Eli Lilly announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3B commitment, increasing the company’s total investment in this site from $3.7B to $9B. “This expansion will enhance Lilly’s capacity to manufacture active pharmaceutical ingredients for Zepbound, or tirzepatide, injection and Mounjaro injection so that more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments,” the company stated. “Since breaking ground at its Lebanon manufacturing site in 2023, Lilly has transformed a significant portion of the nearly 600 acres within the complex into an active construction site. The company expects to begin making medicines in Lebanon toward the end of 2026 – with operations scaling up through 2028,” the Lilly added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly pays $60M upfront for radiopharmaceutical pact with Aktis
- Early notable gainers among liquid option names on May 21st
- Eli Lilly’s mirikizumab shows efficacy in Crohn’s disease
- Hims & Hers soars after announcing $199 weight loss shots
- Jefferies healthcare analysts hold an analyst/industry conference call
